site stats

Korlym pa criteria

WebRequests for prior authorization of Korlym will be approved as follows: 1. Initial approvals of requests for prior authorization of Korlym will be limited to 8 months of therapy … WebCriteria will be applied consistent with current AASLD/IDSA guidance PART B PREREQUSITE N/A PAGE 21 LAST UPDATED 01/2024. LEDIPASVIR/SOFOSBUVIR (HARVONI) ... KORLYM PA INDICATION INDICATOR 3 - All Medically-Accepted Indications OFF LABEL USES N/A EXCLUSION CRITERIA N/A REQUIRED MEDICAL …

Self-Administered Specialty Pharmacy Drug List

WebOtherwise please return completed form to: UPMC HEALTH PLAN PHARMACY SERVICES PHONE 800-396-4139 FAX 412-454-7722 Web1. Currently receiving medication via PA Health & Wellness benefit or member has previously met all initial approval criteria; or the Continuity of Care policy … therapeutic pedagogy https://reneevaughn.com

2024 Service Benefit Plan Specialty Drug List

WebCorcept Therapeutics Inc. is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. Corcept has focused on the adverse effects of excess cortisol, studying new compounds that may mitigate those effects. Its executive team is … WebKorlym (mifepristone) Effective 10/01/2024 . Plan ☐ MassHealth UPPL ... Authorization may be granted if the member meets all following criteria and documentation has been ... 7/22/20 – Reviewed and Updated July P&T Mtg; Updated Program Type to PA and QL. Effective 10/01/2024 . 9/16/20 – Reviewed at September P&T, Updated ... WebKorlymis indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. signs of heat illness

Clinical Policy: Mifepristone (Korlym) - PA Health & Wellness

Category:NeedyMeds

Tags:Korlym pa criteria

Korlym pa criteria

Self-Administered Specialty Pharmacy Drug List

Web1 dec. 2024 · Korlym (mifepristone) is a cortisol receptor blocker indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous … WebMedical Necessity Criteria . Mifepristone (Korlym) is considered medically necessary when ONE of the following is met (1, 2, or 3): 1. Endogenous Cushing’s Syndrome. Individual meets ALL of the following criteria: A. Age 18 years or older B. Korlym is being used to control hyperglycemia secondary to hypercortisolism in individuals who

Korlym pa criteria

Did you know?

Webmonths if the individual meets the following criteria (A and B): A) Individual is ≥ 18 years of age; AND B) Korlym is prescribed by or in consultation with an endocrinologist or … WebCushing’s – Korlym PA Policy Page 2 adrenocorticotropic hormone (ACTH) secretion.13 The use of these drugs is limited by variable efficacy and adverse events (AEs). The impairment of glucose metabolism generally resolves with normalization of …

WebKorlym PA Kuvan PA Lanreotide PA Lupron Pediatric PA Makena PA Mycapssa PA Myalept PA Natpara PA Nityr PA Parsabiv Procysbi PA Recorlev PA Samsca PA Sandostatin PA ... Dysport PA Pregnyl PA Inflammatory conditions Actemra PA Acthar PA Adbry PA Avsola PA Cibinqo PA Cimzia Cortrophin PA Cosentyx PA Dupixent PA … WebKORLYM is supplied as a light yellow to yellow, film-coated, oval-shaped tablet debossed with “Corcept” on one side and “300” on the other. Each tablet contains 300 mg of mifepristone. KORLYM tablets are available in bottles of 28 tablets (NDC 76346-073-01) and bottles of 280 tablets (NDC 76346-073-02).

WebCriteria for Approval: 1. Diagnosis of Cushing’s syndrome; AND 2. Diagnosis of type 2 diabetes mellitus or glucose intolerance; AND 3. Has failed surgery or is not a … WebKorlym (mifepristone) is a cortisol receptor blocker indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome …

Web27 jan. 2012 · and affirmed that although a REMS is required for Mifeprex, a REMS for Korlym is not necessary to ensure that the benefits of the drug outweigh its risks at this time. Korlym’s safety and drug utilization should use be monitored through post marketing requirements (PMR). If data indicate that the current approach compromises the …

WebKorlymis indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose … therapeutic pharmaceuticalstherapeutic peptides examplesWebKorlym (mifepristone) is used to control high blood sugar levels (hyperglycemia) in adults with endogenous Cushing’s syndrome. The drug was approved for use in patients with endogenous Cushing’s syndrome who have type 2 diabetes or glucose intolerance and are not candidates for surgery or who have not responded to prior surgery. signs of heart scarring